Global Gliosarcoma Market

Gliosarcoma Comprehensive Study by Type (Primary Gliosarcoma, Secondary Gliosarcoma), Treatment (Surgery, Radiation, Chemotherapy, Immunotherapy Drugs), End-users (Hospitals, Clinics, Ambulatory Surgical Centres), Symptoms (Headache, Seizures, Weakness, Numbness, Others) Players and Region - Global Market Outlook to 2030

Gliosarcoma Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Gliosarcoma
Gliosarcoma is a rare type of primary central nervous system (CNS) tumor that begins in the brain or spinal cord. Gliosarcoma is a glioma. These tumors are classified as Grade IV tumors. It is a variant of glioblastoma (along with epithelioid glioblastoma and giant cell glioblastoma) recognized in the WHO classification of CNS tumors. The symptoms may involve headaches, weakness, seizures, thinking or memory difficulties, numbness, or problems with balance and movement.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Gliosarcoma market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Roche Holding AG (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), Arbor Pharmaceuticals, LLC (United States), Merck & Co., Inc. (United States), Sun Pharmaceutical Industries Ltd (India), Amgen Inc. (United States), Teva Pharmaceutical Industries Ltd (Israel), Genentech, Inc. (United States), Cadila Healthcare Limited (India) and Intas Biopharmaceuticals (India) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Edge Pharma Pvt. (India) and Pfizer Inc. (United States).

Segmentation Overview
AMA Research has segmented the market of Global Gliosarcoma market by Type (Primary Gliosarcoma and Secondary Gliosarcoma) and Region.



On the basis of geography, the market of Gliosarcoma has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Treatment, the sub-segment i.e. Surgery will boost the Gliosarcoma market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End-users, the sub-segment i.e. Hospitals will boost the Gliosarcoma market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Symptoms, the sub-segment i.e. Headache will boost the Gliosarcoma market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increasing Number of Research Activities in the Medical Field

Market Growth Drivers:
Increasing Number of Patients with Gliosarcoma, Increasing Number of Diagnostic Centres and Increasing Healthcare Expenditure Across Emerging Markets

Challenges:
Stringent Regulatory Scenario

Restraints:
Limited Patient Awareness Related to Disease Diagnosis and Dearth of Skilled and Well-Trained Professionals

Opportunities:
Growing Target Patient Population, Continuous Product Development and Commercialization and Growth in the Healthcare Industry

Market Leaders and their expansionary development strategies
In November 2023, Gamma Therapeutics, a company developing CAR-T cell therapy for glioblastoma, announced a merger with Adaptimmune, a leading cell therapy company. This combined entity aims to leverage expertise and resources to accelerate the development of glioblastoma treatments.
In December 2023, Merck and Tizona Therapeutics entered a strategic partnership to develop and commercialize a novel CD137 agonist antibody for solid tumors, including gliosarcoma. This collaboration combines Merck's clinical development and commercialization expertise with Tizona's discovery and early development capabilities.


Key Target Audience
Gliosarcoma Treatment Providers, Distributors, Emerging Companies, Research Professionals and End-users

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Primary Gliosarcoma
  • Secondary Gliosarcoma
By Treatment
  • Surgery
  • Radiation
  • Chemotherapy
  • Immunotherapy Drugs

By End-users
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centres

By Symptoms
  • Headache
  • Seizures
  • Weakness
  • Numbness
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Number of Patients with Gliosarcoma
      • 3.2.2. Increasing Number of Diagnostic Centres
      • 3.2.3. Increasing Healthcare Expenditure Across Emerging Markets
    • 3.3. Market Challenges
      • 3.3.1. Stringent Regulatory Scenario
    • 3.4. Market Trends
      • 3.4.1. Increasing Number of Research Activities in the Medical Field
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Gliosarcoma, by Type, Treatment, End-users, Symptoms and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Gliosarcoma (Value)
      • 5.2.1. Global Gliosarcoma by: Type (Value)
        • 5.2.1.1. Primary Gliosarcoma
        • 5.2.1.2. Secondary Gliosarcoma
      • 5.2.2. Global Gliosarcoma by: Treatment (Value)
        • 5.2.2.1. Surgery
        • 5.2.2.2. Radiation
        • 5.2.2.3. Chemotherapy
        • 5.2.2.4. Immunotherapy Drugs
      • 5.2.3. Global Gliosarcoma by: End-users (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinics
        • 5.2.3.3. Ambulatory Surgical Centres
      • 5.2.4. Global Gliosarcoma by: Symptoms (Value)
        • 5.2.4.1. Headache
        • 5.2.4.2. Seizures
        • 5.2.4.3. Weakness
        • 5.2.4.4. Numbness
        • 5.2.4.5. Others
      • 5.2.5. Global Gliosarcoma Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Gliosarcoma: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Roche Holding AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. F. Hoffmann-La Roche Ltd (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Arbor Pharmaceuticals, LLC (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Merck & Co., Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sun Pharmaceutical Industries Ltd (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Amgen Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Teva Pharmaceutical Industries Ltd (Israel)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Genentech, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Cadila Healthcare Limited (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Intas Biopharmaceuticals (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Gliosarcoma Sale, by Type, Treatment, End-users, Symptoms and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Gliosarcoma (Value)
      • 7.2.1. Global Gliosarcoma by: Type (Value)
        • 7.2.1.1. Primary Gliosarcoma
        • 7.2.1.2. Secondary Gliosarcoma
      • 7.2.2. Global Gliosarcoma by: Treatment (Value)
        • 7.2.2.1. Surgery
        • 7.2.2.2. Radiation
        • 7.2.2.3. Chemotherapy
        • 7.2.2.4. Immunotherapy Drugs
      • 7.2.3. Global Gliosarcoma by: End-users (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinics
        • 7.2.3.3. Ambulatory Surgical Centres
      • 7.2.4. Global Gliosarcoma by: Symptoms (Value)
        • 7.2.4.1. Headache
        • 7.2.4.2. Seizures
        • 7.2.4.3. Weakness
        • 7.2.4.4. Numbness
        • 7.2.4.5. Others
      • 7.2.5. Global Gliosarcoma Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Gliosarcoma: by Type(USD Million)
  • Table 2. Gliosarcoma Primary Gliosarcoma , by Region USD Million (2018-2023)
  • Table 3. Gliosarcoma Secondary Gliosarcoma , by Region USD Million (2018-2023)
  • Table 4. Gliosarcoma: by Treatment(USD Million)
  • Table 5. Gliosarcoma Surgery , by Region USD Million (2018-2023)
  • Table 6. Gliosarcoma Radiation , by Region USD Million (2018-2023)
  • Table 7. Gliosarcoma Chemotherapy , by Region USD Million (2018-2023)
  • Table 8. Gliosarcoma Immunotherapy Drugs , by Region USD Million (2018-2023)
  • Table 9. Gliosarcoma: by End-users(USD Million)
  • Table 10. Gliosarcoma Hospitals , by Region USD Million (2018-2023)
  • Table 11. Gliosarcoma Clinics , by Region USD Million (2018-2023)
  • Table 12. Gliosarcoma Ambulatory Surgical Centres , by Region USD Million (2018-2023)
  • Table 13. Gliosarcoma: by Symptoms(USD Million)
  • Table 14. Gliosarcoma Headache , by Region USD Million (2018-2023)
  • Table 15. Gliosarcoma Seizures , by Region USD Million (2018-2023)
  • Table 16. Gliosarcoma Weakness , by Region USD Million (2018-2023)
  • Table 17. Gliosarcoma Numbness , by Region USD Million (2018-2023)
  • Table 18. Gliosarcoma Others , by Region USD Million (2018-2023)
  • Table 19. South America Gliosarcoma, by Country USD Million (2018-2023)
  • Table 20. South America Gliosarcoma, by Type USD Million (2018-2023)
  • Table 21. South America Gliosarcoma, by Treatment USD Million (2018-2023)
  • Table 22. South America Gliosarcoma, by End-users USD Million (2018-2023)
  • Table 23. South America Gliosarcoma, by Symptoms USD Million (2018-2023)
  • Table 24. Brazil Gliosarcoma, by Type USD Million (2018-2023)
  • Table 25. Brazil Gliosarcoma, by Treatment USD Million (2018-2023)
  • Table 26. Brazil Gliosarcoma, by End-users USD Million (2018-2023)
  • Table 27. Brazil Gliosarcoma, by Symptoms USD Million (2018-2023)
  • Table 28. Argentina Gliosarcoma, by Type USD Million (2018-2023)
  • Table 29. Argentina Gliosarcoma, by Treatment USD Million (2018-2023)
  • Table 30. Argentina Gliosarcoma, by End-users USD Million (2018-2023)
  • Table 31. Argentina Gliosarcoma, by Symptoms USD Million (2018-2023)
  • Table 32. Rest of South America Gliosarcoma, by Type USD Million (2018-2023)
  • Table 33. Rest of South America Gliosarcoma, by Treatment USD Million (2018-2023)
  • Table 34. Rest of South America Gliosarcoma, by End-users USD Million (2018-2023)
  • Table 35. Rest of South America Gliosarcoma, by Symptoms USD Million (2018-2023)
  • Table 36. Asia Pacific Gliosarcoma, by Country USD Million (2018-2023)
  • Table 37. Asia Pacific Gliosarcoma, by Type USD Million (2018-2023)
  • Table 38. Asia Pacific Gliosarcoma, by Treatment USD Million (2018-2023)
  • Table 39. Asia Pacific Gliosarcoma, by End-users USD Million (2018-2023)
  • Table 40. Asia Pacific Gliosarcoma, by Symptoms USD Million (2018-2023)
  • Table 41. China Gliosarcoma, by Type USD Million (2018-2023)
  • Table 42. China Gliosarcoma, by Treatment USD Million (2018-2023)
  • Table 43. China Gliosarcoma, by End-users USD Million (2018-2023)
  • Table 44. China Gliosarcoma, by Symptoms USD Million (2018-2023)
  • Table 45. Japan Gliosarcoma, by Type USD Million (2018-2023)
  • Table 46. Japan Gliosarcoma, by Treatment USD Million (2018-2023)
  • Table 47. Japan Gliosarcoma, by End-users USD Million (2018-2023)
  • Table 48. Japan Gliosarcoma, by Symptoms USD Million (2018-2023)
  • Table 49. India Gliosarcoma, by Type USD Million (2018-2023)
  • Table 50. India Gliosarcoma, by Treatment USD Million (2018-2023)
  • Table 51. India Gliosarcoma, by End-users USD Million (2018-2023)
  • Table 52. India Gliosarcoma, by Symptoms USD Million (2018-2023)
  • Table 53. South Korea Gliosarcoma, by Type USD Million (2018-2023)
  • Table 54. South Korea Gliosarcoma, by Treatment USD Million (2018-2023)
  • Table 55. South Korea Gliosarcoma, by End-users USD Million (2018-2023)
  • Table 56. South Korea Gliosarcoma, by Symptoms USD Million (2018-2023)
  • Table 57. Taiwan Gliosarcoma, by Type USD Million (2018-2023)
  • Table 58. Taiwan Gliosarcoma, by Treatment USD Million (2018-2023)
  • Table 59. Taiwan Gliosarcoma, by End-users USD Million (2018-2023)
  • Table 60. Taiwan Gliosarcoma, by Symptoms USD Million (2018-2023)
  • Table 61. Australia Gliosarcoma, by Type USD Million (2018-2023)
  • Table 62. Australia Gliosarcoma, by Treatment USD Million (2018-2023)
  • Table 63. Australia Gliosarcoma, by End-users USD Million (2018-2023)
  • Table 64. Australia Gliosarcoma, by Symptoms USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Gliosarcoma, by Type USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Gliosarcoma, by Treatment USD Million (2018-2023)
  • Table 67. Rest of Asia-Pacific Gliosarcoma, by End-users USD Million (2018-2023)
  • Table 68. Rest of Asia-Pacific Gliosarcoma, by Symptoms USD Million (2018-2023)
  • Table 69. Europe Gliosarcoma, by Country USD Million (2018-2023)
  • Table 70. Europe Gliosarcoma, by Type USD Million (2018-2023)
  • Table 71. Europe Gliosarcoma, by Treatment USD Million (2018-2023)
  • Table 72. Europe Gliosarcoma, by End-users USD Million (2018-2023)
  • Table 73. Europe Gliosarcoma, by Symptoms USD Million (2018-2023)
  • Table 74. Germany Gliosarcoma, by Type USD Million (2018-2023)
  • Table 75. Germany Gliosarcoma, by Treatment USD Million (2018-2023)
  • Table 76. Germany Gliosarcoma, by End-users USD Million (2018-2023)
  • Table 77. Germany Gliosarcoma, by Symptoms USD Million (2018-2023)
  • Table 78. France Gliosarcoma, by Type USD Million (2018-2023)
  • Table 79. France Gliosarcoma, by Treatment USD Million (2018-2023)
  • Table 80. France Gliosarcoma, by End-users USD Million (2018-2023)
  • Table 81. France Gliosarcoma, by Symptoms USD Million (2018-2023)
  • Table 82. Italy Gliosarcoma, by Type USD Million (2018-2023)
  • Table 83. Italy Gliosarcoma, by Treatment USD Million (2018-2023)
  • Table 84. Italy Gliosarcoma, by End-users USD Million (2018-2023)
  • Table 85. Italy Gliosarcoma, by Symptoms USD Million (2018-2023)
  • Table 86. United Kingdom Gliosarcoma, by Type USD Million (2018-2023)
  • Table 87. United Kingdom Gliosarcoma, by Treatment USD Million (2018-2023)
  • Table 88. United Kingdom Gliosarcoma, by End-users USD Million (2018-2023)
  • Table 89. United Kingdom Gliosarcoma, by Symptoms USD Million (2018-2023)
  • Table 90. Netherlands Gliosarcoma, by Type USD Million (2018-2023)
  • Table 91. Netherlands Gliosarcoma, by Treatment USD Million (2018-2023)
  • Table 92. Netherlands Gliosarcoma, by End-users USD Million (2018-2023)
  • Table 93. Netherlands Gliosarcoma, by Symptoms USD Million (2018-2023)
  • Table 94. Rest of Europe Gliosarcoma, by Type USD Million (2018-2023)
  • Table 95. Rest of Europe Gliosarcoma, by Treatment USD Million (2018-2023)
  • Table 96. Rest of Europe Gliosarcoma, by End-users USD Million (2018-2023)
  • Table 97. Rest of Europe Gliosarcoma, by Symptoms USD Million (2018-2023)
  • Table 98. MEA Gliosarcoma, by Country USD Million (2018-2023)
  • Table 99. MEA Gliosarcoma, by Type USD Million (2018-2023)
  • Table 100. MEA Gliosarcoma, by Treatment USD Million (2018-2023)
  • Table 101. MEA Gliosarcoma, by End-users USD Million (2018-2023)
  • Table 102. MEA Gliosarcoma, by Symptoms USD Million (2018-2023)
  • Table 103. Middle East Gliosarcoma, by Type USD Million (2018-2023)
  • Table 104. Middle East Gliosarcoma, by Treatment USD Million (2018-2023)
  • Table 105. Middle East Gliosarcoma, by End-users USD Million (2018-2023)
  • Table 106. Middle East Gliosarcoma, by Symptoms USD Million (2018-2023)
  • Table 107. Africa Gliosarcoma, by Type USD Million (2018-2023)
  • Table 108. Africa Gliosarcoma, by Treatment USD Million (2018-2023)
  • Table 109. Africa Gliosarcoma, by End-users USD Million (2018-2023)
  • Table 110. Africa Gliosarcoma, by Symptoms USD Million (2018-2023)
  • Table 111. North America Gliosarcoma, by Country USD Million (2018-2023)
  • Table 112. North America Gliosarcoma, by Type USD Million (2018-2023)
  • Table 113. North America Gliosarcoma, by Treatment USD Million (2018-2023)
  • Table 114. North America Gliosarcoma, by End-users USD Million (2018-2023)
  • Table 115. North America Gliosarcoma, by Symptoms USD Million (2018-2023)
  • Table 116. United States Gliosarcoma, by Type USD Million (2018-2023)
  • Table 117. United States Gliosarcoma, by Treatment USD Million (2018-2023)
  • Table 118. United States Gliosarcoma, by End-users USD Million (2018-2023)
  • Table 119. United States Gliosarcoma, by Symptoms USD Million (2018-2023)
  • Table 120. Canada Gliosarcoma, by Type USD Million (2018-2023)
  • Table 121. Canada Gliosarcoma, by Treatment USD Million (2018-2023)
  • Table 122. Canada Gliosarcoma, by End-users USD Million (2018-2023)
  • Table 123. Canada Gliosarcoma, by Symptoms USD Million (2018-2023)
  • Table 124. Mexico Gliosarcoma, by Type USD Million (2018-2023)
  • Table 125. Mexico Gliosarcoma, by Treatment USD Million (2018-2023)
  • Table 126. Mexico Gliosarcoma, by End-users USD Million (2018-2023)
  • Table 127. Mexico Gliosarcoma, by Symptoms USD Million (2018-2023)
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Gliosarcoma: by Type(USD Million)
  • Table 139. Gliosarcoma Primary Gliosarcoma , by Region USD Million (2025-2030)
  • Table 140. Gliosarcoma Secondary Gliosarcoma , by Region USD Million (2025-2030)
  • Table 141. Gliosarcoma: by Treatment(USD Million)
  • Table 142. Gliosarcoma Surgery , by Region USD Million (2025-2030)
  • Table 143. Gliosarcoma Radiation , by Region USD Million (2025-2030)
  • Table 144. Gliosarcoma Chemotherapy , by Region USD Million (2025-2030)
  • Table 145. Gliosarcoma Immunotherapy Drugs , by Region USD Million (2025-2030)
  • Table 146. Gliosarcoma: by End-users(USD Million)
  • Table 147. Gliosarcoma Hospitals , by Region USD Million (2025-2030)
  • Table 148. Gliosarcoma Clinics , by Region USD Million (2025-2030)
  • Table 149. Gliosarcoma Ambulatory Surgical Centres , by Region USD Million (2025-2030)
  • Table 150. Gliosarcoma: by Symptoms(USD Million)
  • Table 151. Gliosarcoma Headache , by Region USD Million (2025-2030)
  • Table 152. Gliosarcoma Seizures , by Region USD Million (2025-2030)
  • Table 153. Gliosarcoma Weakness , by Region USD Million (2025-2030)
  • Table 154. Gliosarcoma Numbness , by Region USD Million (2025-2030)
  • Table 155. Gliosarcoma Others , by Region USD Million (2025-2030)
  • Table 156. South America Gliosarcoma, by Country USD Million (2025-2030)
  • Table 157. South America Gliosarcoma, by Type USD Million (2025-2030)
  • Table 158. South America Gliosarcoma, by Treatment USD Million (2025-2030)
  • Table 159. South America Gliosarcoma, by End-users USD Million (2025-2030)
  • Table 160. South America Gliosarcoma, by Symptoms USD Million (2025-2030)
  • Table 161. Brazil Gliosarcoma, by Type USD Million (2025-2030)
  • Table 162. Brazil Gliosarcoma, by Treatment USD Million (2025-2030)
  • Table 163. Brazil Gliosarcoma, by End-users USD Million (2025-2030)
  • Table 164. Brazil Gliosarcoma, by Symptoms USD Million (2025-2030)
  • Table 165. Argentina Gliosarcoma, by Type USD Million (2025-2030)
  • Table 166. Argentina Gliosarcoma, by Treatment USD Million (2025-2030)
  • Table 167. Argentina Gliosarcoma, by End-users USD Million (2025-2030)
  • Table 168. Argentina Gliosarcoma, by Symptoms USD Million (2025-2030)
  • Table 169. Rest of South America Gliosarcoma, by Type USD Million (2025-2030)
  • Table 170. Rest of South America Gliosarcoma, by Treatment USD Million (2025-2030)
  • Table 171. Rest of South America Gliosarcoma, by End-users USD Million (2025-2030)
  • Table 172. Rest of South America Gliosarcoma, by Symptoms USD Million (2025-2030)
  • Table 173. Asia Pacific Gliosarcoma, by Country USD Million (2025-2030)
  • Table 174. Asia Pacific Gliosarcoma, by Type USD Million (2025-2030)
  • Table 175. Asia Pacific Gliosarcoma, by Treatment USD Million (2025-2030)
  • Table 176. Asia Pacific Gliosarcoma, by End-users USD Million (2025-2030)
  • Table 177. Asia Pacific Gliosarcoma, by Symptoms USD Million (2025-2030)
  • Table 178. China Gliosarcoma, by Type USD Million (2025-2030)
  • Table 179. China Gliosarcoma, by Treatment USD Million (2025-2030)
  • Table 180. China Gliosarcoma, by End-users USD Million (2025-2030)
  • Table 181. China Gliosarcoma, by Symptoms USD Million (2025-2030)
  • Table 182. Japan Gliosarcoma, by Type USD Million (2025-2030)
  • Table 183. Japan Gliosarcoma, by Treatment USD Million (2025-2030)
  • Table 184. Japan Gliosarcoma, by End-users USD Million (2025-2030)
  • Table 185. Japan Gliosarcoma, by Symptoms USD Million (2025-2030)
  • Table 186. India Gliosarcoma, by Type USD Million (2025-2030)
  • Table 187. India Gliosarcoma, by Treatment USD Million (2025-2030)
  • Table 188. India Gliosarcoma, by End-users USD Million (2025-2030)
  • Table 189. India Gliosarcoma, by Symptoms USD Million (2025-2030)
  • Table 190. South Korea Gliosarcoma, by Type USD Million (2025-2030)
  • Table 191. South Korea Gliosarcoma, by Treatment USD Million (2025-2030)
  • Table 192. South Korea Gliosarcoma, by End-users USD Million (2025-2030)
  • Table 193. South Korea Gliosarcoma, by Symptoms USD Million (2025-2030)
  • Table 194. Taiwan Gliosarcoma, by Type USD Million (2025-2030)
  • Table 195. Taiwan Gliosarcoma, by Treatment USD Million (2025-2030)
  • Table 196. Taiwan Gliosarcoma, by End-users USD Million (2025-2030)
  • Table 197. Taiwan Gliosarcoma, by Symptoms USD Million (2025-2030)
  • Table 198. Australia Gliosarcoma, by Type USD Million (2025-2030)
  • Table 199. Australia Gliosarcoma, by Treatment USD Million (2025-2030)
  • Table 200. Australia Gliosarcoma, by End-users USD Million (2025-2030)
  • Table 201. Australia Gliosarcoma, by Symptoms USD Million (2025-2030)
  • Table 202. Rest of Asia-Pacific Gliosarcoma, by Type USD Million (2025-2030)
  • Table 203. Rest of Asia-Pacific Gliosarcoma, by Treatment USD Million (2025-2030)
  • Table 204. Rest of Asia-Pacific Gliosarcoma, by End-users USD Million (2025-2030)
  • Table 205. Rest of Asia-Pacific Gliosarcoma, by Symptoms USD Million (2025-2030)
  • Table 206. Europe Gliosarcoma, by Country USD Million (2025-2030)
  • Table 207. Europe Gliosarcoma, by Type USD Million (2025-2030)
  • Table 208. Europe Gliosarcoma, by Treatment USD Million (2025-2030)
  • Table 209. Europe Gliosarcoma, by End-users USD Million (2025-2030)
  • Table 210. Europe Gliosarcoma, by Symptoms USD Million (2025-2030)
  • Table 211. Germany Gliosarcoma, by Type USD Million (2025-2030)
  • Table 212. Germany Gliosarcoma, by Treatment USD Million (2025-2030)
  • Table 213. Germany Gliosarcoma, by End-users USD Million (2025-2030)
  • Table 214. Germany Gliosarcoma, by Symptoms USD Million (2025-2030)
  • Table 215. France Gliosarcoma, by Type USD Million (2025-2030)
  • Table 216. France Gliosarcoma, by Treatment USD Million (2025-2030)
  • Table 217. France Gliosarcoma, by End-users USD Million (2025-2030)
  • Table 218. France Gliosarcoma, by Symptoms USD Million (2025-2030)
  • Table 219. Italy Gliosarcoma, by Type USD Million (2025-2030)
  • Table 220. Italy Gliosarcoma, by Treatment USD Million (2025-2030)
  • Table 221. Italy Gliosarcoma, by End-users USD Million (2025-2030)
  • Table 222. Italy Gliosarcoma, by Symptoms USD Million (2025-2030)
  • Table 223. United Kingdom Gliosarcoma, by Type USD Million (2025-2030)
  • Table 224. United Kingdom Gliosarcoma, by Treatment USD Million (2025-2030)
  • Table 225. United Kingdom Gliosarcoma, by End-users USD Million (2025-2030)
  • Table 226. United Kingdom Gliosarcoma, by Symptoms USD Million (2025-2030)
  • Table 227. Netherlands Gliosarcoma, by Type USD Million (2025-2030)
  • Table 228. Netherlands Gliosarcoma, by Treatment USD Million (2025-2030)
  • Table 229. Netherlands Gliosarcoma, by End-users USD Million (2025-2030)
  • Table 230. Netherlands Gliosarcoma, by Symptoms USD Million (2025-2030)
  • Table 231. Rest of Europe Gliosarcoma, by Type USD Million (2025-2030)
  • Table 232. Rest of Europe Gliosarcoma, by Treatment USD Million (2025-2030)
  • Table 233. Rest of Europe Gliosarcoma, by End-users USD Million (2025-2030)
  • Table 234. Rest of Europe Gliosarcoma, by Symptoms USD Million (2025-2030)
  • Table 235. MEA Gliosarcoma, by Country USD Million (2025-2030)
  • Table 236. MEA Gliosarcoma, by Type USD Million (2025-2030)
  • Table 237. MEA Gliosarcoma, by Treatment USD Million (2025-2030)
  • Table 238. MEA Gliosarcoma, by End-users USD Million (2025-2030)
  • Table 239. MEA Gliosarcoma, by Symptoms USD Million (2025-2030)
  • Table 240. Middle East Gliosarcoma, by Type USD Million (2025-2030)
  • Table 241. Middle East Gliosarcoma, by Treatment USD Million (2025-2030)
  • Table 242. Middle East Gliosarcoma, by End-users USD Million (2025-2030)
  • Table 243. Middle East Gliosarcoma, by Symptoms USD Million (2025-2030)
  • Table 244. Africa Gliosarcoma, by Type USD Million (2025-2030)
  • Table 245. Africa Gliosarcoma, by Treatment USD Million (2025-2030)
  • Table 246. Africa Gliosarcoma, by End-users USD Million (2025-2030)
  • Table 247. Africa Gliosarcoma, by Symptoms USD Million (2025-2030)
  • Table 248. North America Gliosarcoma, by Country USD Million (2025-2030)
  • Table 249. North America Gliosarcoma, by Type USD Million (2025-2030)
  • Table 250. North America Gliosarcoma, by Treatment USD Million (2025-2030)
  • Table 251. North America Gliosarcoma, by End-users USD Million (2025-2030)
  • Table 252. North America Gliosarcoma, by Symptoms USD Million (2025-2030)
  • Table 253. United States Gliosarcoma, by Type USD Million (2025-2030)
  • Table 254. United States Gliosarcoma, by Treatment USD Million (2025-2030)
  • Table 255. United States Gliosarcoma, by End-users USD Million (2025-2030)
  • Table 256. United States Gliosarcoma, by Symptoms USD Million (2025-2030)
  • Table 257. Canada Gliosarcoma, by Type USD Million (2025-2030)
  • Table 258. Canada Gliosarcoma, by Treatment USD Million (2025-2030)
  • Table 259. Canada Gliosarcoma, by End-users USD Million (2025-2030)
  • Table 260. Canada Gliosarcoma, by Symptoms USD Million (2025-2030)
  • Table 261. Mexico Gliosarcoma, by Type USD Million (2025-2030)
  • Table 262. Mexico Gliosarcoma, by Treatment USD Million (2025-2030)
  • Table 263. Mexico Gliosarcoma, by End-users USD Million (2025-2030)
  • Table 264. Mexico Gliosarcoma, by Symptoms USD Million (2025-2030)
  • Table 265. Research Programs/Design for This Report
  • Table 266. Key Data Information from Secondary Sources
  • Table 267. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Gliosarcoma: by Type USD Million (2018-2023)
  • Figure 5. Global Gliosarcoma: by Treatment USD Million (2018-2023)
  • Figure 6. Global Gliosarcoma: by End-users USD Million (2018-2023)
  • Figure 7. Global Gliosarcoma: by Symptoms USD Million (2018-2023)
  • Figure 8. South America Gliosarcoma Share (%), by Country
  • Figure 9. Asia Pacific Gliosarcoma Share (%), by Country
  • Figure 10. Europe Gliosarcoma Share (%), by Country
  • Figure 11. MEA Gliosarcoma Share (%), by Country
  • Figure 12. North America Gliosarcoma Share (%), by Country
  • Figure 13. Global Gliosarcoma share by Players 2023 (%)
  • Figure 14. Global Gliosarcoma share by Players (Top 3) 2023(%)
  • Figure 15. Global Gliosarcoma share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 18. Roche Holding AG (Switzerland) Revenue: by Geography 2023
  • Figure 19. F. Hoffmann-La Roche Ltd (Switzerland) Revenue, Net Income and Gross profit
  • Figure 20. F. Hoffmann-La Roche Ltd (Switzerland) Revenue: by Geography 2023
  • Figure 21. Arbor Pharmaceuticals, LLC (United States) Revenue, Net Income and Gross profit
  • Figure 22. Arbor Pharmaceuticals, LLC (United States) Revenue: by Geography 2023
  • Figure 23. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Merck & Co., Inc. (United States) Revenue: by Geography 2023
  • Figure 25. Sun Pharmaceutical Industries Ltd (India) Revenue, Net Income and Gross profit
  • Figure 26. Sun Pharmaceutical Industries Ltd (India) Revenue: by Geography 2023
  • Figure 27. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Amgen Inc. (United States) Revenue: by Geography 2023
  • Figure 29. Teva Pharmaceutical Industries Ltd (Israel) Revenue, Net Income and Gross profit
  • Figure 30. Teva Pharmaceutical Industries Ltd (Israel) Revenue: by Geography 2023
  • Figure 31. Genentech, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Genentech, Inc. (United States) Revenue: by Geography 2023
  • Figure 33. Cadila Healthcare Limited (India) Revenue, Net Income and Gross profit
  • Figure 34. Cadila Healthcare Limited (India) Revenue: by Geography 2023
  • Figure 35. Intas Biopharmaceuticals (India) Revenue, Net Income and Gross profit
  • Figure 36. Intas Biopharmaceuticals (India) Revenue: by Geography 2023
  • Figure 37. Global Gliosarcoma: by Type USD Million (2025-2030)
  • Figure 38. Global Gliosarcoma: by Treatment USD Million (2025-2030)
  • Figure 39. Global Gliosarcoma: by End-users USD Million (2025-2030)
  • Figure 40. Global Gliosarcoma: by Symptoms USD Million (2025-2030)
  • Figure 41. South America Gliosarcoma Share (%), by Country
  • Figure 42. Asia Pacific Gliosarcoma Share (%), by Country
  • Figure 43. Europe Gliosarcoma Share (%), by Country
  • Figure 44. MEA Gliosarcoma Share (%), by Country
  • Figure 45. North America Gliosarcoma Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Roche Holding AG (Switzerland)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Arbor Pharmaceuticals, LLC (United States)
  • Merck & Co., Inc. (United States)
  • Sun Pharmaceutical Industries Ltd (India)
  • Amgen Inc. (United States)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • Genentech, Inc. (United States)
  • Cadila Healthcare Limited (India)
  • Intas Biopharmaceuticals (India)
Additional players considered in the study are as follows:
Edge Pharma Pvt. (India) , Pfizer Inc. (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 185 Pages 54 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Gliosarcoma Market Quantitative research analysis
Global Gliosarcoma Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Roche Holding AG (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), Arbor Pharmaceuticals, LLC (United States), Merck & Co., Inc. (United States), Sun Pharmaceutical Industries Ltd (India), Amgen Inc. (United States), Teva Pharmaceutical Industries Ltd (Israel), Genentech, Inc. (United States), Cadila Healthcare Limited (India) and Intas Biopharmaceuticals (India) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increasing Number of Research Activities in the Medical Field" is seen as one of major influencing trends for Gliosarcoma Market during projected period 2023-2030.
The Gliosarcoma market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Gliosarcoma Market Report?

Have a Query? Click Here

Other Related Reports

Localized Scleroderma Comprehensive Study by Type (Morphea, Linear Scleroderma), Treatment (Creams, Ointments, Phototherapy, Steroids, Medication), End-users (Hospitals, Clinics, Others), Distributio...
$ 3650
Partial Epilepsy Comprehensive Study by Condition (Epilepsy Drug Resistant/Intractable Epilepsy, Others), End Use (Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Centers), End User (Adul...
$ 3500
Ataxia Comprehensive Study by Type (Cerebellar Ataxia, Sensory Ataxia, Vestibular Ataxia), Treatment (Adaptive Devices, Therapies (Physical Therapy, Occupational Therapy and Speech Therapy), Medicati...
$ 3750
Post Herpetic Neuralgia Treatment Comprehensive Study by Type (Patches (Capsaicin Skin Patches and Lidocaine Skin Patches), Drugs, Opioids), Application (Hospitals, Clinics, Others), Distribution Cha...
$ 3450
Dried Blood Spot Collection Cards Comprehensive Study by Type (Ahlstrom 226, Whatman 903, Flinders Technology Associates (FTA), Others), Application (Forensics, Infectious Disease Testing, Newborn Sc...
$ 3650
Deep Wrinkle Fillers Comprehensive Study by Type (Hyaluronic Acid, Synthetic, Collagen, Autologous), Application (Hospital, Dermatology Clinics, Beauty Salon), Form (Cream, Injectable) Players and Re...
$ 3500